Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kapulasheng quadruple therapy for Helicobacter pylori eradication
ChiCTR2400092707Phase 4Recruiting
- Sponsor
- Tianjin Integrated Traditional Chinese and Western Medicine Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of keverprazan in Helicobacter pylori infection (2 arms), sponsored by Tianjin Integrated Traditional Chinese and Western Medicine Hospital. Primary endpoint: Helicobacter pylori status by breath test. Started Nov 2024; status: recruiting.
02
Drugs
keverprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2400092707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092707.